Alerts
COVID-19 update
See our updated visitor policy, which allows 1 visitor per patient during exams only and includes masking for all. No visitors are allowed in treatment (applies at all locations). Only exceptions are patients with physical or mental disability.
Skip Navigation

The AIM-HN and SEQ-HN Study: A 2 Cohort, Non-comparative, Pivotal Study Evaluating the Efficacy of Tipifarnib in Patients with Head and Neck Squamous Cell Carcinoma HNSCC with HRAS Mutations AIM-HN and the Impact of HRAS Mutations on Response to First Line Systemic Therapies for HNSCC SEQ-HN.

Brief Summary

Type:
Other

Study Type:
Treatment

Phase:
II

ClinicalTrials.gov Identifier:
NCT03719690

Study #:
STUDY00143047

Start Date:
Apr 02, 2019

Full Details and Eligibility at clinicaltrials.gov

By taking part in a clinical trial, you have access to potentially effective treatments not available elsewhere. Additionally, you will contribute to cancer research, which can help other cancer patients in the future. Read the full details of this specific clinical trial by clicking on the link below.

ClinicalTrials.gov ID: NCT03719690

View Complete Trial Details & Eligibility at ClinicalTrials.gov